Chapel Allerton Hospital

Running trials

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014)

  NCT07176390· Phase 2· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

  NCT06747949· Phase 3· Amgen· Source

• Active, not recruiting

  Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)

  NCT06843239· Phase 2· Zura Bio Inc· Source

• Active, not recruiting

  A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06718101· Phase 2· AbbVie· Source

• Recruiting

  DERMATOMICS: Identifying Regulators of Skin Homeostasis

  NCT06894654· Relation Therapeutics· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

  NCT06655155· Phase 2· argenx· Source

• Active, not recruiting

  A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

  NCT06245408· Phase 3· Amgen· Source

• Recruiting

  British Axial Spondyloarthritis Inception Cohort

  NCT05676775· The Leeds Teaching Hospitals NHS Trust· Source

• Active, not recruiting

  GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

  NCT05686551· Phase 2· Hoffmann-La Roche· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Active, not recruiting

  Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

  NCT05270668· Phase 2· Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

  NCT04963296· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

  NCT04929210· Phase 4· Janssen Research & Development, LLC· Source

• Active, not recruiting

  The CCP Study: Coordinated Programme to Prevent Arthritis - Can We Identify Arthritis at a Pre-clinical Stage ?

  NCT02012764· University of Leeds· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Systemic sclerosis (scleroderma)2 recruiting
• Ankylosing spondylitis1 recruiting
• Sjögren's disease1 recruiting

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity

  NCT06104124· Phase 3· Amgen· Source

• Completed

  A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms

  NCT05559580· Phase 2· Boehringer Ingelheim· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Psoriatic arthritis12 works · 1 trial